Page 189 of 1,034: studies 1,881 to 1,890 of 10,336, newest first. Back to the depression overview
Nursing Open January 24, 2023 Hui Liu, L. Kong, Qian Sun et al.
This meta‐analysis aimed to determine the effect of mindfulness interventions on nurses' levels of depression and anxiety.
Pharmaceuticals January 24, 2023 Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała 10 citations
There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions in specific subpopulations. The aim of this study was to investigate the safety of intravenous ketamine treatment in relation to dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and Bipolar depression (BP) with...
Cancer Nursing January 23, 2023 Bixia Zhang, Xiaohuan Jin, X. Kuang et al.
Background Emerging evidence supports that virtual reality (VR)–based meditation interventions may improve anxiety and depression among patients with cancer. However, empirical studies involving patients with acute leukemia during induction chemotherapy are limited. Objective This study aimed to examine the effects of VR-based meditation intervention on alleviating anxiety and depression and...
Pharmacoeconomics January 20, 2023 Carla Rognoni, Camilla Falivena, Francesco Costa et al.
Aim: Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasal spray plus SSRI/SNRI antidepressants (ADs) compared with SSRI/SNRI plus placebo nasal spray in...
Molecular Psychiatry January 20, 2023 Jie Guo, Di Qiu, Han-Wen Gu et al. 46 citations
Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials...
The World Journal of Biological Psychiatry January 18, 2023 Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo et al. 61 citations
Abstract Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intravenous ketamine. In this systematic review, we aim to evaluate the efficacy, tolerability, and safety of oral ketamine, esketamine and...
International Journal of Research in Medical Sciences January 17, 2023 Ubaid Rasool, Neelofer Jan, Marya Zahoor et al. 3 citations
Background: Treatment resistant depression can be a life-threatening condition as it leads to an increase of suicide attempts by two to three folds. It has been estimated that nearly 1 million people die due to suicide every year, and more than two-third of these cases occur when the person is undergoing a major depressive episode. Ketamine is an NMDA receptor antagonist, an anesthetic agent...
medRxiv January 17, 2023 Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al. 2 citations preprint
Abstract IMPORTANCE Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear. OBJECTIVE To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment. DESIGN, SETTING, AND PARTICIPANTS This...
AIDASCO Reviews January 17, 2023 Dragana Marković, Eleonora Čapelja 2 citations
Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Beside MDD, psilocybin can alleviate...
Journal of Psychedelic Studies January 16, 2023 Madeline Brendle, Anya Ragnhildstveit, Matthew Slayton et al. 7 citations
Ketamine and esketamine have garnered interest in both psychiatric research and clinical practice for treatment-resistant depression (TRD). In this review, we examined registered trials investigating the therapeutic use of ketamine or esketamine for TRD, with the aim of characterizing emerging trends and knowledge gaps.The ClinicalTrials.gov electronic registry and results database was queried...